BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 7978535)

  • 1. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis.
    Bernstein JA; Kagen SL; Bernstein DI; Bernstein IL
    Ann Allergy; 1994 Nov; 73(5):423-8. PubMed ID: 7978535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy.
    Gorska L; Chelminska M; Kuziemski K; Skrzypski M; Niedoszytko M; Damps-Konstanska I; Szymanowska A; Siemińska A; Wajda B; Drozdowska A; Jutel M; Jassem E
    Int Arch Allergy Immunol; 2008; 147(3):241-5. PubMed ID: 18594155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venom immunotherapy: tolerance to a 3-day protocol of rush-immunotherapy.
    Díez Gómez ML; Quirce Gancedo S; Juliá de Páramo B
    Allergol Immunopathol (Madr); 1995; 23(6):277-84. PubMed ID: 8579006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Results of hyposensitization with bee and wasp venom].
    Adolph J; Dehnert I; Fischer JF; Wenz W
    Z Erkr Atmungsorgane; 1986; 166(1):119-24. PubMed ID: 3953108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
    Ruëff F; Wenderoth A; Przybilla B
    J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hymenoptera venom allergy.
    Przybilla B; Ruëff F
    J Dtsch Dermatol Ges; 2010 Feb; 8(2):114-27; quiz 128-30. PubMed ID: 19751222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific ultrarush desensitization in Hymenoptera venom-allergic patients.
    Schiavino D; Nucera E; Pollastrini E; De Pasquale T; Buonomo A; Bartolozzi F; Lombardo C; Roncallo C; Patriarca G
    Ann Allergy Asthma Immunol; 2004 Apr; 92(4):409-13. PubMed ID: 15104191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunotherapy against hymenoptera venom: report of ten patients].
    Guzmán M MA; Salinas L J; Toche P P; Marinovic M MA; Gallardo O AM
    Rev Med Chil; 2007 Dec; 135(12):1566-71. PubMed ID: 18357358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G; Sin BA; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic and local reactions of bee venom immunotherapy in Iran.
    Bemanian MH; Farhoudi A; Pourpak Z; Gharagozlou M; Movahedi M; Nabavi M; Mozafari H; Mohammadzadeh I; Chavoshzadeh Z; Shirkhoda Z
    Iran J Allergy Asthma Immunol; 2007 Dec; 6(4):203-6. PubMed ID: 18094443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
    Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
    Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A modified ultra-rush-protocol of allergen immunotherapy in children and adolescents with insect venom allergy].
    Steiss JO; Hüls G; Gortner L; Lindemann H
    Klin Padiatr; 2004; 216(2):79-82. PubMed ID: 15106079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
    Goldberg A; Confino-Cohen R
    J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.
    Roesch A; Boerzsoenyi J; Babilas P; Landthaler M; Szeimies RM
    J Dtsch Dermatol Ges; 2008 Apr; 6(4):292-7. PubMed ID: 18042250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simple 3-day "rush" venom immunotherapy protocol: documentation of safety.
    Kalogeromitros D; Makris M; Koti I; Chliva C; Mellios A; Avgerinou G; Theoharides TC
    Allergol Immunopathol (Madr); 2010; 38(2):69-73. PubMed ID: 19853357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of immunotherapy with venom in children with allergy to insect stings.
    Valentine MD; Schuberth KC; Kagey-Sobotka A; Graft DF; Kwiterovich KA; Szklo M; Lichtenstein LM
    N Engl J Med; 1990 Dec; 323(23):1601-3. PubMed ID: 2098016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy.
    Goldberg A; Confino-Cohen R
    Ann Allergy Asthma Immunol; 2003 Oct; 91(4):405-10. PubMed ID: 14582821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk assessment of Hymenoptera re-sting frequency: implications for decision-making in venom immunotherapy.
    von Moos S; Graf N; Johansen P; Müllner G; Kündig TM; Senti G
    Int Arch Allergy Immunol; 2013; 160(1):86-92. PubMed ID: 22948338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy control of specific hymenoptera venom allergy].
    Aust W; Wichmann G; Dietz A
    Laryngorhinootologie; 2010 Dec; 89(12):725-8. PubMed ID: 21132618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
    Goldberg A; Yogev A; Confino-Cohen R
    Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.